Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Operating Expenses (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Operating Expenses for 17 consecutive years, with $152.5 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 19.69% to $152.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $963.8 million through Dec 2025, up 35.98% year-over-year, with the annual reading at $963.8 million for FY2025, 35.96% up from the prior year.
  • Operating Expenses for Q4 2025 was $152.5 million at Myriad Genetics, down from $167.1 million in the prior quarter.
  • The five-year high for Operating Expenses was $481.0 million in Q2 2025, with the low at -$8.2 million in Q4 2023.
  • Average Operating Expenses over 5 years is $197.3 million, with a median of $193.8 million recorded in 2022.
  • The sharpest move saw Operating Expenses tumbled 129.29% in 2023, then skyrocketed 2415.85% in 2024.
  • Over 5 years, Operating Expenses stood at $203.9 million in 2021, then crashed by 86.27% to $28.0 million in 2022, then tumbled by 129.29% to -$8.2 million in 2023, then surged by 2415.85% to $189.9 million in 2024, then dropped by 19.69% to $152.5 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $152.5 million, $167.1 million, and $481.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.